036480 — Daesung Microbiological Labs Co Balance Sheet
0.000.00%
- KR₩32bn
- KR₩43bn
- KR₩24bn
Annual balance sheet for Daesung Microbiological Labs Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 10,052 | 9,935 | 12,859 | 11,727 | 9,053 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3,892 | 3,114 | 3,251 | 4,285 | 3,958 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 23,757 | 23,722 | 28,690 | 28,717 | 23,641 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 35,285 | 35,846 | 33,303 | 32,124 | 31,944 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 62,263 | 62,620 | 65,109 | 64,290 | 58,379 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4,578 | 5,315 | 10,611 | 10,398 | 4,530 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 25,952 | 25,616 | 26,272 | 26,942 | 23,230 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Total Equity | 36,311 | 37,004 | 38,837 | 37,349 | 35,149 |
Total Liabilities & Shareholders' Equity | 62,263 | 62,620 | 65,109 | 64,290 | 58,379 |
Total Common Shares Outstanding |